Dexamethasone, a low-cost steroid drug, has emerged as a life-saver in the fight against the deadly Covid-19 pandemic. A UK based research has confirmed that administrating low-dosage of Dexamethasone has the potential to help patients. The treatment, according to the clinical trial known as RECOVERY, reduces the death rate by around one third among those with the most severe cases of COVID-19 infection.
Chief Medical Officer for England Prof Chris Whitty said, “This is the most important trial result for COVID-19 so far. Significant reduction in mortality in those requiring oxygen or ventilation from a widely available, safe and well-known drug… It will save lives around the world.”
Dexamethasone offers a new hope till the time a fully potent vaccine is developed. At the moment, there is no approved drug for the treatment of coronavirus patients. Many vaccine candidates have reached various stages of trials, But the experts believe that an effective vaccine could only be developed by 2021.
Dexamethasone has been found to help high-risk patients who require oxygen or mechanical ventilation. The drug is already used to reduce inflammation in a range of other conditions, including arthritis, asthma, Multiple Sclerosis etc. As per the research, Dexamethasone halts the damage that can happen when the body’s immune system tries too hard to fight off coronavirus. Inflammation is a worrying symptom of COVID-19, which happens in moderate to severe cases.
According to the NHS, “steroid tablets, also called corticosteroid tablets, are a type of anti-inflammatory medicine used to treat a range of conditions. They can be used to treat problems such as allergies, asthma, eczema, inflammatory bowel disease and arthritis.”
Meanwhile, Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, also announced progress on late-stage development of mRNA-1273, the Company’s mRNA vaccine candidate against COVID-19. Other pharma companies that are working on coronavirus drug are Johnson & Johnson and AstraZeneca in association with the University of Oxford.
Also Read: Immunizations during the Covid-19 pandemic